The main aim of the SynbiCITE Centre will be to provide a bridge between academia and industry to speed up the development of new technologies in synthetic biology. This is a field of science where researchers re-engineer cells to develop microscopic devices that can be used to address a range of global challenges such as producing low-carbon fuel, reducing the cost of industrial raw materials and producing new pharmaceuticals.
SynbiCITE will also be a national resource, involving researchers from a further 17 universities and academic institutions across the UK as well as 13 industrial partners, including the research arms of Microsoft, Shell and GlaxoSmithKline.
“The UK is a global leader in synthetic biology and we hope the establishment of SynbiCITE will help us to capitalise on our research success. The centre will also act as a hub, providing a valuable resource for researchers across the UK,” said Professor Freemont.
SynbiCITE receives £10 million funding from the Engineering and Physical Sciences Research Council and the Biotechnology and Biological Sciences Research Council and the Technology Strategy Board. A further £14 million has been promised by industry.